Literature DB >> 2963167

Plasma levels and dialysance of atrial natriuretic peptide in terminal renal failure.

H Saxenhofer1, M P Gnädinger, P Weidmann, S Shaw, D Schohn, C Hess, D E Uehlinger, H Jahn.   

Abstract

Plasma immunoreactive atrial natriuretic peptide (irANP) levels, their chromatographic profile, relationship with hemodynamic variables, and responses to hemodialysis (HD) or postural changes were investigated in HD patients. Peripheral venous supine plasma irANP averaged 167 +/- 31 (+/- SEM) pg/ml in 12 normal subjects (age 63 +/- 2 yr). In 42 HD patients (mean age 65 +/- 1 yr), plasma irANP in peripheral arterio-venous fistulae was high (447 +/- 50 pg/ml, P less than 0.01) before HD and decreased (P less than 0.001) to 164 +/- 24 pg/ml after HD. The latter reduced body weight by -2.3 +/- 0.2 kg (P less than 0.001) and blood pressure from 139/77 +/- 4/2 to 126/73 +/- 4/2 mm Hg (P less than 0.01). Pre-dialysis plasma irANP in right atrium, pulmonary artery or avfistula correlated with pulmonary capillary wedge pressure (N = 10, r = 0.66 to 0.73; P less than 0.05); HD-induced changes in these variables were also correlated (r = 0.80 to 0.90; P less than 0.05 to less than 0.01). Compared with supine values, upright posture decreased plasma irANP in 12 normal subjects and 8 HD patients (-40 and -42%, respectively, P less than 0.01). IrANP clearance from plasma averaged 24 +/- 5 ml/min across the hemodialyzer (N = 6) and 46 +/- 3 ml/min across the hemofilter (N = 4). We conclude that in terminal renal failure, circulating irANP consists largely of alpha ANP, is often elevated before HD, decreases with the change from recumbency to standing, falls after removal of excess fluid, and may depend strongly on left atrial and pulmonary arterial pressures.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2963167     DOI: 10.1038/ki.1987.244

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  7 in total

1.  Effects of atrial natriuretic peptide on systemic and renal hemodynamics and renal excretory function in patients with chronic renal failure.

Authors:  H Meyer-Lehnert; T Bayer; H G Predel; K Glänzer; H J Kramer
Journal:  Klin Wochenschr       Date:  1991-11-26

2.  [Modification of atrial natriuretic peptide (ANP) and cyclic GMP by hemofiltration and hemodialysis].

Authors:  T Eisenhauer; J Talartschik; E Quentin; W Kreutzfeldt; F Scheler
Journal:  Klin Wochenschr       Date:  1988-09-15

3.  Increased brain natriuretic peptide and atrial natriuretic peptide plasma concentrations in dialysis-dependent chronic renal failure and in patients with elevated left ventricular filling pressure.

Authors:  C Haug; A Metzele; J Steffgen; M Kochs; V Hombach; A Grünert
Journal:  Clin Investig       Date:  1994-06

4.  Atrial natriuretic peptide (ANP) in patients with chronic renal failure on maintenance haemodialysis.

Authors:  R de Châtel; J Makó; M Tóth; I Barna; R E Lang
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

5.  The role of natriuretic peptides in volume assessment and mortality prediction in Haemodialysis patients.

Authors:  Murugan Sivalingam; Enric Vilar; Suresh Mathavakkannan; Ken Farrington
Journal:  BMC Nephrol       Date:  2015-12-29       Impact factor: 2.388

Review 6.  Natriuretic Peptides as Biomarkers for Congestive States: The Cardiorenal Divergence.

Authors:  Abhilash Koratala; Amir Kazory
Journal:  Dis Markers       Date:  2017-06-18       Impact factor: 3.434

7.  Vascular refilling coefficient is not a good marker of whole-body capillary hydraulic conductivity in hemodialysis patients: insights from a simulation study.

Authors:  Leszek Pstras; Jacek Waniewski; Bengt Lindholm
Journal:  Sci Rep       Date:  2022-09-10       Impact factor: 4.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.